Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. President and CEO Kevin J. Knopp reported open-market sales of an aggregate 149,013 shares of common stock over August 10–12, 2026, at weighted average prices around $9.06–$10.16, in transactions made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. An additional 541,223 shares are reported as indirectly owned through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed the beneficial owner.
A shareholder of MASS filed a notice to sell 140,000 shares of common stock through Merrill Lynch, with an indicated aggregate market value of $1,347,000. The filing lists 37,813,621 common shares outstanding and contemplates sales beginning on August 11, 2026 on NASDAQ.
The form identifies the securities as Founder Shares originally acquired from the issuer for cash on February 10, 2012. It also discloses prior open-market sales by Kevin Knopp over the past three months, including multiple transactions between June 23 and August 10, 2026.
908 Devices Inc. develops handheld and program devices for chemical analysis serving defense, public safety and industrial customers. For the six months ended June 30, 2026, revenue from continuing operations was $29.5 million, up from $24.8 million, driven mainly by handheld product sales. Q2 revenue was $16.1 million.
The company reported a continuing-operations net loss of $23.8 million for the first half of 2026 and an accumulated deficit of $247.2 million. Results were pressured by operating expenses of $40.9 million, including a $12.8 million non-cash increase in contingent consideration tied to recent acquisitions.
Liquidity remains solid with $63.0 million of cash and $38.5 million of marketable securities and positive operating cash flow of $4.4 million in the first half. The company closed the NIRLAB acquisition, expanding narcotics-detection capabilities, and continues to recognize the effects of its 2025 Desktop Portfolio divestiture and related transition services. A new $20 million undrawn revolving credit facility extends financial flexibility.
908 Devices Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $16.1 million, up 23% year-over-year, driven by VipIR product demand and initial NIRLab contribution. The installed base grew 23% to 4,101 devices, including 198 devices placed in the quarter, and recurring revenue represented 31% of total revenue.
GAAP gross profit was $8.3 million with a 52% gross margin, while adjusted gross margin improved to 57%. Operating expenses were $21.2 million, including a sizeable noncash charge from the change in fair value of contingent consideration, leading to a net loss from continuing operations of $11.9 million. Adjusted EBITDA loss narrowed to $1.9 million, more than half the prior-year level.
The company held $101.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, with no debt, after using $13.5 million for the NIRLAB SA acquisition and receiving $3.5 million from an escrow release. Full-year 2026 revenue guidance was raised at the low end to $68.0–$70.0 million, representing 21%–25% growth versus 2025.
Christopher Brown filed a Form 144 indicating an intention to sell 100,000 shares of MASS common stock, originally acquired as founders shares, through Morgan Stanley Smith Barney LLC’s Executive Financial Services. The filing lists 37,813,621 MASS common shares outstanding and places the proposed sale value at $888,000.00, with prior sales in recent months executed under a Rule 10b5-1 trading plan.
908 Devices Inc. director Christopher D. Brown reported selling 20,000 shares of common stock on August 5, 2026 at a weighted average price of $8.49 per share, with trade prices ranging from $8.35 to $8.595. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025 and left Brown with 823,359 shares of common stock held directly.
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc., reported an indirect sale of 50,000 shares of Common Stock on August 4, 2026 at a weighted average price of $8.3553 per share. The shares are held through limited partnerships advised by AWM, which reported aggregate post-transaction holdings of 4,829,773 shares and disclaimed beneficial ownership except to the extent of its pecuniary interest.
908 Devices Inc. director Brandi C. Vann exercised Restricted Stock Units into 5,192 shares of Common Stock on August 1, 2026. Each RSU represents a contingent right to one share and vests in substantially equal annual installments over three years following August 1, 2025. After this transaction, Vann reported holdings of 10,385 RSUs and 5,192 shares of Common Stock, all held directly.
BlackRock, Inc. reports a passive ownership stake in 908 Devices Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 1,940,690 shares, representing 5.1% of the outstanding common stock. It has sole voting power over 1,917,820 shares and sole dispositive power over all 1,940,690 shares, with no shared voting or dispositive power reported. Various underlying clients and funds have rights to dividends or sale proceeds, but no single client holds more than five percent of 908 Devices’ outstanding common shares.
908 Devices Inc. issued 3,213,583 shares of common stock to satisfy the earnout consideration tied to its acquisition of RedWave Technology. These shares fulfill the company’s obligations under the April 29, 2024 Equity Purchase Agreement with CAM3 HoldCo, LLC and related sellers. The earnout was based on revenue from certain RedWave products and services over the period from May 1, 2024 through April 30, 2026, measured against a $37 million revenue threshold set in the agreement. With this issuance, the company states that its earnout obligations under the purchase agreement are now fully satisfied.